Sequoia Financial Advisors LLC lessened its position in Elevance Health, Inc. (NYSE:ELV – Free Report) by 26.0% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,625 shares of the company’s stock after selling 2,327 shares during the period. Sequoia Financial Advisors LLC’s holdings in Elevance Health were worth $1,939,000 as of its most recent filing with the SEC.
Several other large investors have also made changes to their positions in ELV. Murphy Middleton Hinkle & Parker Inc. bought a new position in shares of Elevance Health in the fourth quarter valued at approximately $5,941,000. Bright Rock Capital Management LLC bought a new stake in Elevance Health during the 4th quarter worth approximately $7,362,000. Prana Capital Management LP increased its holdings in Elevance Health by 798.9% during the 3rd quarter. Prana Capital Management LP now owns 51,633 shares of the company’s stock valued at $16,684,000 after purchasing an additional 45,889 shares in the last quarter. CIBC Bancorp USA Inc. acquired a new stake in Elevance Health during the 3rd quarter valued at $10,047,000. Finally, Mirabella Financial Services LLP raised its position in Elevance Health by 186.6% in the 3rd quarter. Mirabella Financial Services LLP now owns 8,413 shares of the company’s stock valued at $2,713,000 after purchasing an additional 5,478 shares during the last quarter. Institutional investors own 89.24% of the company’s stock.
Insider Activity at Elevance Health
In other news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $401.77, for a total value of $60,667.27. Following the transaction, the director owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This represents a 1.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.34% of the company’s stock.
Elevance Health News Summary
- Positive Sentiment: Elevance Health beat Q2 estimates, reporting EPS of $7.45 versus $6.18 expected and revenue of $49.83 billion versus $48.84 billion projected. Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Positive Sentiment: The company raised its 2026 adjusted EPS guidance to at least $27.00, suggesting management expects improved operating performance and better medical cost control ahead. Elevance raises annual profit forecast on better medical cost management
- Positive Sentiment: Management said results were supported by disciplined execution, improved operating performance, and lower medical costs in some plans, which could help margins recover. Elevance Health Profits Eclipse $1.4 Billion As Costs Ease Somewhat
- Neutral Sentiment: Elevance also announced a quarterly dividend of $1.72 per share, reinforcing its shareholder-return profile. MarketBeat dividend notice
- Negative Sentiment: Despite the beat, the stock is being pressured by margin concerns, including a higher benefit-expense ratio and ongoing cost pressure in parts of the business. Elevance Health Raises Earnings Outlook on Higher Sales
- Negative Sentiment: Year-over-year EPS fell from $8.84, and softer membership plus higher expenses suggest earnings momentum is not yet fully stable. ELV Beats Q2 Earnings Estimates on Higher CarelonRx Product Revenues
Elevance Health Stock Performance
Elevance Health stock opened at $389.85 on Thursday. The company has a market cap of $84.66 billion, a PE ratio of 16.58, a PEG ratio of 2.42 and a beta of 0.67. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $436.24. The company’s 50-day moving average is $399.67 and its two-hundred day moving average is $355.07.
Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 EPS for the quarter, topping the consensus estimate of $6.21 by $1.24. The company had revenue of $49.83 billion during the quarter, compared to analysts’ expectations of $48.88 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. Elevance Health’s revenue was up .8% on a year-over-year basis. During the same quarter in the previous year, the company earned $8.84 EPS. Equities analysts anticipate that Elevance Health, Inc. will post 26.86 earnings per share for the current year.
Elevance Health Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Thursday, September 10th will be issued a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. The ex-dividend date of this dividend is Thursday, September 10th. Elevance Health’s payout ratio is currently 29.26%.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on ELV shares. Robert W. Baird increased their target price on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a report on Thursday, April 23rd. Raymond James Financial set a $450.00 price target on Elevance Health in a report on Tuesday, July 7th. Guggenheim upped their price target on shares of Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a research report on Friday, April 24th. JPMorgan Chase & Co. increased their price objective on shares of Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Finally, Leerink Partners set a $364.00 price objective on shares of Elevance Health in a research report on Thursday, April 23rd. Fifteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $435.05.
Get Our Latest Analysis on Elevance Health
Elevance Health Profile
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Featured Stories
- Five stocks we like better than Elevance Health
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
